Skip to main content
. 2010 Sep 28;103(8):1201–1208. doi: 10.1038/sj.bjc.6605909

Table 1. Patient characteristics.

  Pat. No. Age Type T-Stage N-Stage ER PRa HER -2 Grading Response Response group
Discovery set 1 61 Lobular 4b + + + 2 SD NR
  2 41 Ductal 4b 3 PR R
  3 52 Ductal 3 + 3 pCR R
  4 30 Ductal 3 + Amplified 2 PR R
  5 56 Lobular 3 + + 2 PR R
  6 74 Lobular 2 + + + 3 SD NR
  7 51 Ductal 2 3 PR R
  8 68 Ductal 2 3 pCR R
  9 37 Ductal 2 3 SD NR
  10 46 Lobular 2 + + 3 SD NR
  11 52 Ductal 2 + 3 SD NR
  12 60 Ductal 3 + + 1 PD NR
Validation set 13 51 Ductal 2 3 PCR R
  14 53 Ductal 2 + 3 PR R
  15 62 Ductal 2 + + 2 PR R
  16 51 Ductal 2 + 3 SD NR
  17 48 Ductal 3 + + Amplified 2 PCR R
  18 40 Ductal 2 + + + 2 SD NR
  19 30 Ductal 2 3 SD NR
  20 59 Lobular 2 + + + 2 SD NR
  21 66 Ductal 2 + 3 PR R
  22 58 Lobular 3 + + Amplified 2 PR R
  23 50 Lobular 2 + + 2 SD NR
  24 52 Ductal 2 + + + 2 PD NR
  25 38 Ductal 2 + + 3 SD NR

Abbreviations: ER=oestrogen receptor; HER-2=human epidermal growth factor receptor; pCR=complete pathological remission; PD=progressive disease; NR=nonresponder; PR=partial remission; R=responder; SD=stable disease.

a

Progesterone receptor.